Genotoxicity assessment of vaccine adjuvant squalene

D Yüzbaşıoğlu1, F Ünal, F Koç

  • 1Faculty of Science, Department of Biology, Genetic Toxicology Laboratory, Gazi University, 06500 Teknikokullar, Ankara, Turkey. deniz@gazi.edu.tr

Insights

Squalene, a vaccine adjuvant, showed no genotoxic effects in human lymphocytes via chromosomal aberration and micronucleus tests. However, further in vivo studies are needed to confirm its safety profile.

Area of Science:

  • Toxicology
  • Immunology
  • Genetics

Background:

  • Vaccine adjuvants play a crucial role in enhancing immune responses.
  • Squalene is a commonly used adjuvant in various vaccines.
  • Assessing the genotoxic potential of vaccine components is vital for safety.

Purpose of the Study:

  • To evaluate the genotoxic potential of squalene in human and rat lymphocytes.
  • To investigate the effects of squalene on chromosomal aberrations, sister chromatid exchanges, and micronucleus formation.
  • To assess DNA damage using the comet assay.

Main Methods:

  • In vitro and in vivo assays were performed on human and rat lymphocytes.
  • Chromosomal aberrations (CAs), sister chromatid exchanges (SCEs), and micronucleus (MNs) tests were conducted.
  • Comet assay was used to measure DNA damage (comet tail length and intensity).

Main Results:

  • Squalene did not induce chromosomal aberrations or micronucleus formation in human lymphocytes.
  • A significant increase in sister chromatid exchanges was observed at most concentrations.
  • Comet assay results showed mixed effects in vitro and in vivo, with no consistent DNA damage.
  • Squalene was not considered genotoxic in human lymphocytes based on the in vitro data.

Conclusions:

  • Squalene demonstrated a lack of genotoxicity in human lymphocytes for chromosomal aberrations and micronucleus tests.
  • The observed increase in sister chromatid exchanges warrants further investigation.
  • Additional in vivo studies are necessary to definitively ascertain the genotoxic effects of squalene.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...